首页> 外文期刊>Life sciences >Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area.
【24h】

Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area.

机译:氯氮平与NMDA受体的甘氨酸位点相互作用:大鼠腹侧被盖区多巴胺神经元的电生理研究。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Clozapine has a remarkable efficacy in treatment-resistant schizophrenia and is one of the most effective antipsychotic drugs used today. The clinical effects of clozapine are suggested to be related to a unique interaction with a variety of receptor systems, including the glutamatergic receptors. Kynurenic acid (KYNA) is an endogenous blocker of alpha7 nicotinic receptors and a glutamate-receptor antagonist, preferentially blocking N-methyl-D-aspartate (NMDA) receptors. In the present in vivo electrophysiological study, changes in endogenous concentration of brain KYNA were utilized to analyze an interaction between clozapine and the glycine site of NMDA receptors. In control rats intravenously administered clozapine (0.078-10 mg/kg) increased the firing rate and the burst firing activity of dopamine (DA) neurons in the ventral tegmental area (VTA). Pretreatment with indomethacin (50 mg/kg, i.p., 1-3.5 h), a cyclooxygenase (COX)-inhibitor with a preferential selectivity for COX-1, which produced a significant elevation in brain KYNA levels, reversed the excitatory action of clozapine into an inhibitory response. In contrast, pretreatment with the COX-2 selective inhibitor parecoxib (25 mg/kg, i.v., 1-1.5 h) decreased brain KYNA formation and furthermore, clearly potentiated the excitatory effect of clozapine. Our results show that endogenous levels of brain KYNA are of importance for the response of clozapine on VTA DA neurons. On the basis of the present data we propose that clozapine is able to interact with glutamatergic mechanisms, via actions at the NMDA/glycine receptor.
机译:氯氮平在抗精神分裂症的治疗中具有显着功效,并且是当今使用的最有效的抗精神病药物之一。氯氮平的临床效果被认为与多种受体系统(包括谷氨酸能受体)的独特相互作用有关。尿酸(KYNA)是alpha7烟碱样受体和谷氨酸受体拮抗剂的内源性阻断剂,优先阻断N-甲基-D-天冬氨酸(NMDA)受体。在目前的体内电生理研究中,利用大脑KYNA内源性浓度的变化来分析氯氮平与NMDA受体甘氨酸位点之间的相互作用。在对照大鼠中,静脉内施用氯氮平(0.078-10 mg / kg)可提高腹侧被盖区(VTA)的放电速度和多巴胺(DA)神经元的爆发放电活性。用吲哚美辛(50 mg / kg,腹腔注射,1-3.5 h)进行预处理,这是一种对COX-1具有优先选择性的环加氧酶(COX)抑制剂,可显着提高脑KYNA水平,从而将氯氮平的兴奋作用逆转为抑制反应。相反,用COX-2选择性抑制剂parecoxib(25 mg / kg,i.v.,1-1.5 h)预处理可减少大脑KYNA的形成,此外,还明显增强了氯氮平的兴奋作用。我们的结果表明,内源性大脑KYNA水平对于氯氮平对VTA DA神经元的反应至关重要。根据目前的数据,我们建议氯氮平能够通过对NMDA /甘氨酸受体的作用与谷氨酸能机制相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号